Literature DB >> 10806591

Effectiveness of low dose of gonadotropin releasing hormone agonist on hormonal flare-up.

B Bständig1, I Cédrin-Durnerin, J N Hugues.   

Abstract

PURPOSE: The hormonal response (flare-up) following administration of a standard dose (100 micrograms) or a low dose (25 micrograms) of gonadotropin releasing hormone agonist (GnRH-a) (Triptorelin) was compared in patients prior to an in vitro fertilization (IVF) cycle and during the early follicular phase of a short-term IVF protocol.
METHODS: The gonadotroph (FSH, LH) and steroid [estradiol (E2) and progesterone (P)] flare-up was studied on two consecutive cycles in 30 normo-ovulatory women. Patients were randomized to receive either 25 or 100 micrograms of triptorelin for three days at the beginning of the first cycle. Then doses were switched according to a crossing over design in the second cycle.
RESULTS: No significant difference in the magnitude of FSH and E2 release could be observed following administration of the two doses of agonist whereas maximal plasma LH level was significantly reduced after injection of 25 micrograms of triptorelin.
CONCLUSIONS: As compared to a standard dose, using a low dose of GnRH-a induces an hormonal flare-up which seems adequate for an optimal follicular recruitment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10806591      PMCID: PMC3455162          DOI: 10.1023/a:1009470101732

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN: 1058-0468            Impact factor:   3.412


  20 in total

1.  The hormonal flare-up following gonadotrophin-releasing hormone agonist administration is influenced by a progestogen pretreatment.

Authors:  I Cédrin-Durnerin; S Bulwa; F Hervé; B Martin-Pont; M Uzan; J N Hugues
Journal:  Hum Reprod       Date:  1996-09       Impact factor: 6.918

2.  Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.

Authors:  C Bergh; C M Howles; K Borg; L Hamberger; B Josefsson; L Nilsson; M Wikland
Journal:  Hum Reprod       Date:  1997-10       Impact factor: 6.918

3.  A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3.

Authors:  F Olivennes; C Righini; R Fanchin; C Torrisi; A Hazout; M Glissant; H Fernandez; F Frydman
Journal:  Hum Reprod       Date:  1996-06       Impact factor: 6.918

4.  Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol.

Authors:  W Schoolcraft; T Schlenker; M Gee; J Stevens; L Wagley
Journal:  Fertil Steril       Date:  1997-01       Impact factor: 7.329

5.  Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization.

Authors:  E S Surrey; J Bower; D M Hill; J Ramsey; M W Surrey
Journal:  Fertil Steril       Date:  1998-03       Impact factor: 7.329

6.  Gonadotrophin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF.

Authors:  R M Janssens; J P Vermeiden; C B Lambalk; R Schats; J Schoemaker
Journal:  Hum Reprod       Date:  1998-09       Impact factor: 6.918

7.  Follicular atresia associated with concurrent initiation of gonadotropin-releasing hormone agonist and follicle-stimulating hormone for oocyte recruitment.

Authors:  R G Brzyski; S J Muasher; K Droesch; S Simonetti; G S Jones; Z Rosenwaks
Journal:  Fertil Steril       Date:  1988-12       Impact factor: 7.329

8.  Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.

Authors:  A Lemay; A E Metha; G Tolis; N Faure; F Labrie; A T Fazekas
Journal:  Fertil Steril       Date:  1983-05       Impact factor: 7.329

9.  Pituitary response to early follicular-phase minidose gonadotropin releasing hormone agonist (GnRHa) therapy: evidence for a second flare.

Authors:  J L Deaton; P Bauguess; C S Huffman; K A Miller
Journal:  J Assist Reprod Genet       Date:  1996-05       Impact factor: 3.412

10.  Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations.

Authors:  S J Weil; K Vendola; J Zhou; O O Adesanya; J Wang; J Okafor; C A Bondy
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.